179 related articles for article (PubMed ID: 38445610)
1. TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II alpha promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.
Lyu WJ; Shu YJ; Liu YB; Dong P
Chin Med J (Engl); 2020 Oct; 133(19):2321-2329. PubMed ID: 32925281
[TBL] [Abstract][Full Text] [Related]
3. The miRNA mir-582-3p suppresses ovarian cancer progression by targeting AKT/MTOR signaling
Dai T; Liang J; Liu W; Zou Y; Niu F; Li M; Zhang H; Li C; Fan M; Cui G
Bioengineered; 2021 Dec; 12(2):10771-10781. PubMed ID: 34793263
[TBL] [Abstract][Full Text] [Related]
4. TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells.
Weng H; Feng X; Lan Y; Zheng Z
J Ovarian Res; 2021 Jun; 14(1):82. PubMed ID: 34162426
[TBL] [Abstract][Full Text] [Related]
5. Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (
Zhou Y; Li J; Yang X; Song Y; Li H
Bioengineered; 2021 Dec; 12(2):12003-12022. PubMed ID: 34787052
[TBL] [Abstract][Full Text] [Related]
6. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.
Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X
Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130
[TBL] [Abstract][Full Text] [Related]
7. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
8. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
9. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
10. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
11. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
Wang X; Jiang L; Liu Q
J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
[TBL] [Abstract][Full Text] [Related]
12. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract][Full Text] [Related]
14. Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance.
Liu T; Jin ZW; Li Y; Zhang G; Yang XY; Xu XM; Ma YC
J Cancer Res Ther; 2022 Apr; 18(2):488-495. PubMed ID: 35645119
[TBL] [Abstract][Full Text] [Related]
15. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway.
Gao L; Chen M; Ouyang Y; Li R; Zhang X; Gao X; Lin S; Wang X
Life Sci; 2018 Jun; 202():188-194. PubMed ID: 29625193
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of ARHGAP30 inhibits ovarian cancer cell proliferation, migration, and invasiveness by suppressing the PI3K/AKT/mTOR signaling pathway.
Chu X; Lou J; Yi Y; Zhong L; Huang O
Eur J Histochem; 2023 May; 67(2):. PubMed ID: 37170915
[TBL] [Abstract][Full Text] [Related]
18. Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway.
Wei X; Jia Y; Lou H; Ma J; Huang Q; Meng Y; Sun C; Yang Z; Li X; Xu S; Yang X; Ji T; Gao Q
Oncol Rep; 2019 Dec; 42(6):2768-2776. PubMed ID: 31638241
[TBL] [Abstract][Full Text] [Related]
19. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
20. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
